Duration of SARS-CoV-2 Natural Immunity and Protection against the Delta Variant: A Retrospective Cohort Study

Priscilla Kim, BA, MS, Steven M Gordon, MD, Megan M. Sheehan, BS, Michael B. Rothberg, MD, MPH

1Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA
2Department of Infectious Disease, Cleveland Clinic, Cleveland, Ohio, USA
3Center for Value-Based Care Research, Cleveland Clinic, Cleveland, Ohio, USA

Corresponding Author:
Michael B. Rothberg, MD, MPH
Center for Value-Based Care Research
9500 Euclid Ave, Mail Code G10
Cleveland, OH 44195
Phone: 216-445-5556
Email: rothbem@ccf.org

Summary: Previous SARS-CoV-2 infection offers strong protection against symptomatic infection with the Delta variant. Additionally, natural immunity from prior infection lasts for at least 13 months, which is longer than has been previously reported.

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Abstract

Background: Infection with SARS-CoV-2 has been shown to be highly protective against reinfection and symptomatic disease. However, effectiveness against the highly transmissible Delta variant and duration of natural immunity remain unknown.

Methods: This retrospective cohort study included 325,157 patients tested for coronavirus disease 2019 (COVID-19) via polymerase chain reaction (PCR) from 09 March 2020 to 31 December 2020 (Delta variant analysis) and 152,656 patients tested from 09 March 2020 to 30 August 2020 (long-term effectiveness analysis) with subsequent testing through 09 September 2021. The primary outcome was reinfection, defined as a positive PCR test >90 days after initial positive test.

Results: Among 325,157 patients tested before 31 December 2020, 50,327 (15.5%) tested positive. After 01 July 2021 (Delta dominant period), 40 (0.08%) of the initially positive and 1,494 (0.5%) of the initially negative patients tested positive. Protection of prior infection against reinfection with Delta was 85.4% (95% CI, 80.0-89.3). For the long-term effectiveness analysis, among 152,656 patients tested before 30 August 2020, 11,186 (7.3%) tested positive. After at least 90 days, 81 (0.7%) of the initially positive patients and 7,167 (5.1%) of the initially negative patients tested positive. Overall protection of previous infection was 85.7% (95% CI, 82.2-88.5) and lasted up to 13 months. Patients over age 65 had slightly lower protection.

Conclusions: SARS-CoV-2 infection is highly protective against reinfection with the Delta variant. Immunity from prior infection lasts for at least 13 months. Countries facing vaccine shortages should consider delaying vaccinations for previously infected patients to increase access.

Keywords: COVID-19; Delta; reinfection; protective effectiveness; natural immunity
Introduction

Nearly two years after the identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the coronavirus disease 2019 (COVID-19) pandemic remains a major global health challenge due to the emergence of SARS-CoV-2 variants that have been associated with increased transmissibility and potential immune escape. In the United States, these variants of concern have included B.1.1.7 (Alpha), B.1.351 (Beta), B.1.1.28.1 (Gamma) and B.1.617.2 (Delta) [1,2]. The Delta variant, first detected in India in December 2020, has become the predominant variant in the United States, United Kingdom, and several other countries [1]. By July 24, 2021, the Delta variant represented 93.7% of sequenced viruses circulating in the United States [1]. Characterized by multiple spike protein mutations, the Delta variant appears to lead to higher viral loads and increased transmission [3,4].

Previous studies have demonstrated that infection with SARS-CoV-2 is highly protective against reinfection and symptomatic disease [5–9]. Studies from the UK [7,8], US [5], and Denmark [6] all describe approximately 85% reduced risk of reinfection for 5-7 months. Duration of immunity beyond this period is unknown, but recent findings suggest that vaccine-induced immunological responses (e.g. neutralizing antibodies) wane after 6 months [10–13].

Additionally, the protection afforded by prior COVID-19 infection against reinfection with variants of concern is not well-understood. In vitro neutralization assays have shown that the Delta variant has reduced sensitivity to antibodies present in the sera of individuals who have recovered from COVID-19, as well as the sera of vaccinated individuals [2,4]. These findings suggest that natural infection may not offer the same protection against the Delta variant. Understanding the effectiveness of prior infection against Delta is important, as it can inform vaccination strategies in countries with
vaccine constraints and SARS-CoV-2 transmission models. The aim of our study was to determine whether prior infection protects against reinfection with the Delta variant and to estimate duration of immunity following COVID-19 infection.

Methods

Subjects and outcomes

Individuals tested for COVID-19 via polymerase chain reaction (PCR) within the Cleveland Clinic Health System in Ohio and Florida between March 9, 2020, and September 9, 2021, were included. PCR testing was performed on patients who were symptomatic, hospitalized for any reason, required preprocedural screening, or sought international travel clearance. We conducted two analyses following natural infection: one to assess effectiveness against the Delta variant, and one to assess long-term effectiveness. For the Delta analysis, initial status was based on tests performed before December 31, 2020. For the long-term effectiveness analysis, initial infection status was based on tests performed before August 30, 2020. Patients with at least one positive test during these periods were considered initially positive. The primary outcome was a positive PCR retest. According to CDC criteria, reinfection is defined as occurring ≥90 days after initial testing [14]. Therefore, for initially positive patients, any positive test ≥90 days after initial infection was defined as a reinfection. To avoid bias, initially negative patients who retested positive within 90 days of their initial test were excluded.

Data analyses:

For the Delta variant analysis, we selected patients with a positive or negative PCR test before December 31, 2020 (Figure 1). For each group, we then determined retesting and retest positivity rates specifically during the period of Delta predominance – from July 1,
2021, to September 9, 2021. Patients who retested positive were reviewed for hospitalizations, intensive care unit (ICU) admission, need for mechanical ventilation, and death within 30 days of the test. Patients who retested positive between January 1, 2021, and June 30, 2021, were excluded from this analysis. For each group of patients, the infection rate was determined by dividing the number of patients who retested positive by the total number of patients in that group. Protection offered by prior infection against repeat infections was calculated as 1 minus the ratio of infection rate for the initially positive patients to the infection rate for the initially negative patients. Patients who had no subsequent tests were assumed to be negative. To estimate the effectiveness of prior infection against symptomatic infection, we repeated the analysis including only symptomatic infections. For most tests, the ordering physician recorded the presence of symptoms in a questionnaire. Initially positive patients with missing questionnaires were chart reviewed to determine symptoms. For initially negative patients who had missing questionnaires, we imputed the results by chart reviewing a random sample of patients with missing questionnaires to determine the proportion of patients with symptomatic infection, and then applied that proportion to the remaining patients with missing symptomatic data.

To assess whether protection offered by prior infection differs by age, we calculated a protective effect estimate separately for different age groups (age 0-17 years, 18-34 years, 35-50 years, 51-64 years, 65-79 years, and ≥80 years). To increase our power to detect a difference, we compared rates in patients aged 0-64 years to those aged 65 years and above. Because many patients were vaccinated during this period, and vaccination might modify the risk of contracting Delta, we also estimated the protection of prior infection restricted to patients who were documented to have received two doses of the COVID-19 vaccine before July 1, 2021. We limited the vaccination analysis to patients who received two doses of the
COVID-19 vaccine because we were unable to distinguish between patients who were unvaccinated and those who were missing vaccine data, and the type of vaccine that patients received was unknown.

For the long-term effectiveness analysis, patients with a positive or negative PCR test before August 30, 2020, were followed through September 9, 2021, to determine retesting and retest positivity rates during this period. Infection rates and protection offered by prior infection were calculated for distinct time periods using the equations previously described. Protection estimates were also calculated for different age groups. All analyses were conducted using R v4.1.0 (R Core Team, Vienna). The Cleveland Clinic Institutional Review Board approved this work.

**Results**

During the study period, 878,830 PCR tests were collected from 527,134 individuals (average age, 48.8 ± 23.2 years; 55.1% female), with a 10.3% overall positivity rate.

*Delta analysis*

After excluding 781 patients who tested positive between January 1, 2020, and June 30, 2020, there were 471,499 tests performed before December 31, 2020, on 325,157 individuals. Of these, 50,327 (15.5%) individuals tested positive (Table 1). After July 1, 2021, 2,712 (5.4%) of the initially positive patients were retested, and 41 (1.5%) of those patients retested positive; one patient had immediate subsequent negative test results and was thus excluded due to a presumed false-positive test. Of the 40 reinfections, 28 (70%) were symptomatic; the rest had an asymptomatic indication (e.g., preprocedural screening, pre-admission screening
for non-COVID-related diagnosis). Of the 274,830 initially negative patients, 19,157 (7.0%) were retested after July 1, 2021, and 1,494 (7.8%) of those patients retested positive. Of these, 1,298 (86.9%) were symptomatic. Retested patients who had previously been infected were slightly more likely to be symptomatic at the time of retesting than those not previously infected (57.1% vs. 54.0%, p=0.008). The overall protection of prior infection against reinfection during the period of Delta dominance was 85.4% (95% CI, 80.0-89.3). Protection was higher against symptomatic infection (88.2% [95% CI, 82.9-91.9]) than asymptomatic infection (66.6% [95% CI, 40.6-81.2]).

Protection by age is shown in Table 2. There were relatively few patients aged ≥80 years, but the protective effect estimate for patients aged ≥80 years was higher than, but not statistically different from, that of patients aged 65-79 years; the two categories are thus reported together. Compared to patients aged 0-64 years, those aged 65 or older had a lower rate of protection (75.1% vs. 87.9%, p=0.06). The proportion of patients who received 2 doses of COVID-19 vaccine before July 1, 2021, was similar for previously infected and non-infected patients (25.4% vs. 26.6%, p<0.001). Among the vaccinated patients, previous infection had an estimated effectiveness of 86.8% (95% CI, 74.5-93.2) against reinfection with Delta.

Severity of illness within 30 days was similar between those who had and had not been previously infected, including rates of hospitalization (14/40 [35.0%] vs. 587/1494 [39.3%], p=0.58), admission to the ICU (3/14 [21.4%] vs. 94/587 [16.0%], p=0.59), mechanical ventilation (2/14 [14.3%] vs. 38/587 [6.5%], p=0.25), and death (1/14 [7.1%] vs. 25/587 [4.3%], p=0.60).
Long-term effectiveness analysis

There were 199,406 tests performed before August 30, 2020, on 152,656 individuals. Of these, 11,186 (7.3%) tested positive (Table 3). After at least 90 days, 2,187 (19.6%) of the initially positive patients were retested, and 84 (3.8%) of these patients retested positive; three patients had immediate subsequent negative test results and were thus excluded due to presumed false-positive tests. Of the 81 reinfections, 38 (46.9%) were symptomatic. Of the 141,470 initially negative patients, 47,539 (33.6%) individuals were retested, and 7,167 (15.1%) retested positive. Of these, 6,030 (84.1%) were symptomatic. The estimated overall protection against reinfection was 85.7% (95% CI, 82.2-88.5). Again, protection was greater against symptomatic infection (92.0% [95% CI, 89.1-94.2]) than asymptomatic infection (52.2% [95% CI, 35.3-64.7]), particularly during the first 90-150 days, when effectiveness against asymptomatic infection was actually negative. After the first 5 months, protection against reinfection exceeded 90% for up to 13 months from initial infection. Protection by age is shown in Table 4. Again, there were very few cases among patients aged ≥80 years, and their results were combined with patients aged 65-79 years. Protection among those aged ≥65 years was lower than that of individuals under age 65 (76.3% vs. 88.9%, p <0.001).

Discussion

We conducted a large retrospective cohort study of patients tested for COVID-19 at 1 health system to estimate protection of previous infection against the Delta variant and to assess the duration of immunity conferred by SARS-CoV-2 infection. We found that patients with prior infection were less likely to be retested or retest positive compared to individuals who initially tested negative during the same period. Effectiveness of previous infection against symptomatic infection with Delta was 88.2%, which was similar to the protection against symptomatic infection throughout the entire study period (92.0%). Even when asymptomatic
cases were included, protection offered against reinfection with Delta and throughout the entire study period was 85.4% and 85.7%, respectively. After the first 5 months, protection against reinfection exceeded 90% for up to 13 months after primary infection, suggesting that natural immunity lasts longer than has been previously reported [5,7,8]. Effectiveness against repeat infection was slightly reduced in patients aged 65 years and older. Among those who were infected with the Delta variant, severity of illness, as measured by 30-day rates of hospitalization and ICU admission, appeared to be similar between those who had and had not been previously infected. Thus, while prior infection appears to be highly protective against infection with the Delta variant, in contrast to vaccination, it does not appear to reduce severity of disease. Finally, among patients who were fully vaccinated against COVID-19, prior SARS-CoV-2 infection offered an additional 87% protection against infection with the Delta variant.

Several large cohort studies from the United Kingdom, Austria, and Qatar, have reported similar estimates of short-term protection against non-Delta strains [5,7,8,15,16]. Two studies of healthcare workers in the UK demonstrated that immunity from natural infection lasts at least 5-6 months [7,8], and a study of 43,044 antibody-positive individuals in Qatar estimated a 95.2% efficacy of prior infection that can last for at least 7 months [15]. Our study adds to these by assessing the long-term immunity conferred by SARS-CoV-2 infection. We found no evidence of waning protection for up to 13 months. This is consistent with in vitro studies that have demonstrated the persistence of antibodies with neutralizing activity for at least 12 months [17]. Interestingly, we found that protection against reinfection, in particular asymptomatic reinfection, was lowest 3-5 months after initial infection, increasing thereafter. This counterintuitive finding might be explained by persistent viral shedding, as asymptomatic patients can continue to shed virus for many months following initial infection.
[18]; this would have caused us to underestimate protection during this time period and overall.

While *in vitro* neutralization studies have shown that antibodies present in the sera of previously infected individuals are less potent against the Delta variant [2,4], we found that natural infection offers high levels of protection against Delta. In fact, natural infection appears to offer more sustained protection against Delta than vaccine-mediated immunity. Recent studies have shown that vaccine-mediated immunity wanes after 6 months, with a rapid decline in efficacy against Delta after as little as 90 days [10,11,13,19]. This finding is further supported by a large observational study in Israel, which reported that SARS-CoV-2-naive individuals who received two doses of the BioNTech/Pfizer mRNA vaccine were 6 to 13 times more likely to become infected with Delta than patients who had experienced infection previously [20]. Similarly, we found that among vaccinated patients, those who were not previously infected were almost 8 times as likely to be subsequently infected with Delta.

Our study has several limitations. Chief among them is that we do not have access to testing results outside of the Cleveland Clinic Health System. However, unless there was a differential in patients’ seeking testing at the Cleveland Clinic based on their previous infection status, our findings should still be valid. Similarly, some patients may have been infected but not sought testing at all, especially if they were asymptomatic or mildly so. Patients with previous infection may be less likely to seek testing because they think that they are immune, which would result in an overestimation of the protective effect of prior infection. It is also possible that patients with previous infection are more or less likely to forgo vaccination or engage in high-risk behaviors, both of which would be associated with
reinfection risk apart from immunity. However, when we analyzed our results stratified by age, patients aged 18-34 years did not show reduced effectiveness against Delta, even though such patients are more likely to engage in risky behavior [21] and less likely to be vaccinated [22]. Moreover, when analyzing our results among vaccinated patients, the findings were the same. Additionally, because sequencing was not routinely performed on clinical specimens during our study period, it is possible that some positive tests after July 1, 2021, do not represent infection with Delta. However, given that Delta represented 87% of the sequenced viruses in the US by mid-July 2021, with this percentage reaching 96% by July 31, 2021, the vast majority of SARS-CoV-2 infections after July 1 can be assumed to have been caused by Delta [1]. It is also possible that there are specific Delta strains that can escape natural immunity and to which our protective estimates would not apply. Lastly, we were unable to assess the impact of vaccinations because many took place outside of our health system; this constrained our ability to distinguish between missing data and zero vaccine doses. The type of vaccines that patients received was also unknown, so we could not distinguish between patients who received single-dose or two-dose vaccines. Therefore, we limited our vaccination analysis to those patients who had two confirmed date entries for their COVID-19 vaccines.

Our study has several important implications. Most low- and middle-income countries face significant challenges in obtaining adequate supplies of COVID-19 vaccines [23]. Based on our findings, countries with vaccine shortages should consider delaying vaccinations of previously infected individuals to prioritize vaccinating non-immune individuals, beginning with the most vulnerable populations (e.g., elderly patients, those with multiple comorbidities, front-line healthcare workers). Our findings may also have implications for the recent U.S. emergency temporary standard (ETS), which would require large employers to
enforce mandatory COVID-19 vaccination, a policy under which all employees must either be vaccinated against COVID-19 or undergo weekly COVID-19 testing [24]. Patients who have recovered from COVID-19 infection are notably not exempt. This stands in contrast to the policies of several other countries, which acknowledge the immunity provided by prior COVID-19 infection. Israel [25], the European Union (EU) [26], and the United Kingdom [27] all provide some version of a COVID pass, which allows access to public spaces following either vaccination or recovery from COVID-19. Given that previous infection appears to offer sustained protection against the Delta variant, our study suggests that natural immunity should be considered in the U.S. emergency temporary standard.

Our findings also suggest that some countries may approach herd immunity against future variants due to the protection offered by the combination of previous SARS-CoV-2 infections and COVID-19 vaccinations. With an $R_0$ of 6, the Delta variant would require a herd immunity threshold of at least 85% [28,29]. Researchers estimate that about one-third of the U.S. population had been infected with COVID-19 by the end of 2020, and 58.8% of the U.S. population has been fully vaccinated against COVID-19 as of November 15, 2021 [20,30]. Given the many additional cases of COVID-19 in 2021, the U.S. may be approaching herd immunity [31]. However, large-scale vaccination programs are critical for continued progress. A recent phylogenetic analysis of evolutionarily close coronavirus relatives estimated reinfection by SARS-CoV-2 to occur at a median of 16 months following peak antibody response, suggesting that immunity does not last forever [32].

Although our findings highlight the effectiveness of natural immunity, intentional exposure to COVID-19 in order to gain such immunity is not recommended. Recent studies from Canada [33] and Singapore [34] showed that the Delta variant was associated with an increased risk
for hospitalization, ICU admission, oxygen requirement, and death. Therefore, achieving immunity through vaccination is preferred. Unlike natural immunity, vaccination substantially reduces the risk of developing severe disease [35], as well as potential long-term complications of COVID-19 infection [36].

In summary, we found that previous infection with SARS-CoV-2 offers strong protection against reinfection with the highly transmissible Delta variant. We also found that such natural immunity appears to persist for at least 13 months. Together, these results support vaccination efforts that prioritize patients who have no known history of prior infection and suggest that herd immunity may soon be within reach.
Funding

The authors received no financial support for the research or publication of this article.

Potential conflicts of interest

S.M.G. has served on the clinical endpoint committee (CEC) for the Abbott Heartmate 3 M3PAS study. M.B.R. has owned stock in Moderna. All other authors report no potential conflicts of interests. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.
References

1. Centers for Disease Control and Prevention. COVID-19 Variant Proportions | CDC COVID Data Tracker. 2021. Available at https://covid.cdc.gov/covid-data-tracker/#variant-proportions. Accessed 10 August 2021.

2. Yadav PD, Sapkal GN, Ella R, et al. Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin. J Travel Med 2021; Available at: https://academic.oup.com/jtm/advance-article/doi/10.1093/jtm/taab104/6316247. Accessed 9 August 2021.

3. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med 2021; Available at: http://www.nejm.org/doi/10.1056/NEJMoa2108891. Accessed 9 August 2021.

4. Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 2021; Available at: https://www.nature.com/articles/s41586-021-03777-9. Accessed 9 August 2021.

5. Sheehan MM, Reddy AJ, Rothberg MB. Reinfection Rates Among Patients Who Previously Tested Positive for Coronavirus Disease 2019: A Retrospective Cohort Study. Clin Infect Dis 2021; Available at: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab234/6170939. Accessed 9 August 2021.

6. Hansen CH, Michlmayr D, Gubbels SM, Mølbak K, Ethelberg S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. The Lancet 2021; 397:1204–1212.

7. Lumley SF, O’Donnell D, Stoesser NE, et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. N Engl J Med 2021; 384:533–540.

8. Hall VJ, Foulkes S, Charlett A, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). The Lancet 2021; 397:1459–1469.

9. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021; :eabf4063.

10. Levin EG, Lustig Y, Cohen C, et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med 2021; Available at: http://www.nejm.org/doi/10.1056/NEJMoa2114583. Accessed 8 October 2021.

11. Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N Engl J Med 2021; Available at: http://www.nejm.org/doi/10.1056/NEJMoa2114114. Accessed 8 October 2021.

12. Naaber P, Tserel L, Kangro K, et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health - Eur 2021; Available at: https://reader.elsevier.com/reader/sd/pii/S266677622100185X?token=A098541D8F088AE7C3EA15
13. Cohn BA, Cirillo PM, Murphy CC, Krigbaum NY, Wallace AW. SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. Science 2021; Available at: https://www.science.org/doi/epdf/10.1126/science.abm0620?adobe_mc=MCMID%3D532872785069227996744110725192570978909%7CMCORGID%3D242B6472541199F70A4C98A6%2540AdobeOrg%7CTS%3D1636931683. Accessed 14 November 2021.

14. Centers for Disease Control and Prevention. Investigative criteria for suspected cases of SARS-CoV-2 Reinfection (ICR). 2020. Available at https://www.cdc.gov/coronavirus/2019-ncov/php/invest-criteria.html. Accessed 10 August 2021.

15. Abu-Raddad LJ, Chemaitelly H, Coyle P, et al. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. EClinicalMedicine 2021; 35:100861.

16. Pilz S, Chakeri A, Ioannidis JP, et al. SARS-CoV-2 re-infection risk in Austria. Eur J Clin Invest 2021; 51:e13520.

17. Wang Z, Muecksch F, Schaefer-Babajew D, et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 2021; 595:426–431.

18. Plebani M. Persistent viral RNA shedding in COVID-19: Caution, not fear. EBioMedicine 2021; 64:103234.

19. Pouwels KB, Pritchard E, Matthews PC, et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med 2021; Available at: https://www.nature.com/articles/s41591-021-01548-7. Accessed 15 November 2021.

20. Gazit S, Shlezinger R, Perez G, et al. Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections | medRxiv. MedRxiv 2021; Available at: https://www.medrxiv.org/content/10.1101/2021.08.24.21262415v1. Accessed 6 October 2021.

21. Kim JK, Crimmins EM. How does age affect personal and social reactions to COVID-19: Results from the national Understanding America Study. PLOS ONE 2020; 15:e0241950.

22. Adams SH, Schaub JP, Nagata JM, Park MJ, Brindis CD, Irwin CE. Young Adult Perspectives on COVID-19 Vaccinations. J Adolesc Health 2021; 69:511–514.

23. Tagoe ET, Sheikh N, Morton A, et al. COVID-19 Vaccination in Lower-Middle Income Countries: National Stakeholder Views on Challenges, Barriers, and Potential Solutions. Front Public Health 2021; 9:709127.

24. United States Department of Labor. COVID-19 Vaccination and Testing ETS | Occupational Safety and Health Administration. 2021. Available at https://www.osha.gov/coronavirus/ets2. Accessed 15 November 2021.

25. Wilf-Miron R, Myers V, Saban M. Incentivizing Vaccination Uptake: The “Green Pass” Proposal in Israel. JAMA 2021; 325:1503–1504.
26. European Commission. Questions and answers — EU digital covid certificate. Available at https://ec.europa.eu/commission/presscorner/detail/en/QANDA_21_2781. Accessed 15 November 2021.

27. Block J. Vaccinating people who have had covid-19: why doesn’t natural immunity count in the US? BMJ 2021; n2101.

28. del Rio C, Malani PN, Omer SB. Confronting the Delta Variant of SARS-CoV-2, Summer 2021. J Am Med Assoc 2021; 326:1001–1002.

29. Fine P, Eames K, Heymann DL. ‘Herd Immunity’: A Rough Guide. Clin Infect Dis 2011; 52:911–916.

30. Centers for Disease Control and Prevention. COVID-19 Vaccinations in the United States | CDC COVID Data Tracker. 2021. Available at https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-total-admin-rate-total. Accessed 15 November 2021.

31. Borchering RK, Viboud C, Howerton E, et al. Modeling of Future COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Rates and Nonpharmaceutical Intervention Scenarios — United States, April–September 2021. MMWR Morb Mortal Wkly Rep 2021; 70:719–724.

32. Townsend JP, Hassler HB, Wang Z, et al. The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study. Lancet Microbe 2021; S2666524721002196.

33. Fisman DN, Tuite AR. Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada. Can Med Assoc J 2021; Available at: http://www.cmaj.ca/lookup/doi/10.1503/cmaj.211248. Accessed 8 October 2021.

34. Ong SWX, Chiew CJ, Ang LW, et al. Clinical and virological features of SARS-CoV-2 variants of concern: a retrospective cohort study comparing B.1.1.7 (Alpha), B.1.315 (Beta), and B.1.617.2 (Delta). Clin Infect Dis 2021; ciab721.

35. Centers for Disease Control and Prevention. Rates of laboratory-confirmed COVID-19 hospitalizations by vaccination status | CDC COVID Data Tracker. 2021. Available at https://covid.cdc.gov/covid-data-tracker/#covidnet-hospitalizations-vaccination. Accessed 15 November 2021.

36. Raveendran AV, Jayadevan R, Sashidharan S. Long COVID: An overview. Diabetes Metab Syndr 2021; 15:869–875.
Table 1. Characteristics of patients with initial positive vs. negative test in the Delta analysis

| Characteristic                              | Initial Positive Test | Initial Negative Test |
|---------------------------------------------|-----------------------|-----------------------|
| Number of patients                          | 50,327                | 274,830               |
| Age ± SD, y                                 | 48.9 ± 21.1           | 50.3 ± 22.1           |
| Sex female (%)                              | 26,252 (52.2)         | 155,100 (56.4)        |
| Number retested after July 1, 2021 (%)      | 2,712 (5.4)           | 19,157 (7.0)          |
| Age ± SD, y                                 | 50.6 ± 23.4           | 50.0 ± 24.3           |
| Sex female (%)                              | 1,575 (58.1)          | 11,372 (59.4)         |
| Retest positive, any (%)                    | 40 (0.08)             | 1,494 (0.5)           |
| Time to positive retest ± SD, d             | 300.4 ± 75.7          | 349.1 ± 83.0          |
| Retest positive, symptomatic (%)            | 28 (0.06)             | 1,298 (0.5)           |

Effectiveness

- Any infection: 85.4% (95% CI, 80.0-89.3)
- Symptomatic infection: 88.2% (95% CI, 82.9-91.9)
- Asymptomatic infection: 66.6% (95% CI, 40.6-81.2)

Abbreviation: SD, standard deviation
Table 2. Protection against reinfection with the Delta variant by age group

| Age group (years) | Number of patients | Retest positive | Infection rate | Estimated protection |
|-------------------|--------------------|-----------------|----------------|----------------------|
|                   | Initial + | Initial – | Initial + | Initial – | Initial + | Initial – |                |                      |
| Overall           | 50,327    | 274,830     | 40         | 1494        | 0.08%     | 0.5%        | 85.4%          |                      |
| 0-17              | 3,156     | 20,507      | 4          | 153         | 0.1%      | 0.7%        | 83.0%          |                      |
| 18-34             | 11,614    | 56,304      | 6          | 395         | 0.05%     | 0.7%        | 92.6%          |                      |
| 35-50             | 11,618    | 54,592      | 11         | 341         | 0.09%     | 0.6%        | 84.8%          |                      |
| 51-64             | 11,785    | 62,711      | 7          | 285         | 0.06%     | 0.5%        | 86.9%          |                      |
| 0-64              | 38,173    | 194,115     | 28         | 1,174       | 0.07%     | 0.6%        | 87.9%          |                      |
| ≥65               | 12,154    | 80,715      | 12         | 320         | 0.1%      | 0.4%        | 75.1%          |                      |

*p-value comparing age group ≥65 years vs. all patients <65 years = 0.06.*
Table 3. Characteristics of patients with initial positive vs. negative test in the long-term effectiveness analysis

| Characteristic                  | Initial Positive Test | Initial Negative Test |
|--------------------------------|-----------------------|-----------------------|
| Number of patients             | 11,186                | 141,470               |
| Age ± SD, y                    | 50.5 ± 21.0           | 52.8 ± 21.4           |
| Sex female (%)                 | 5,900 (52.7)          | 79,975 (56.5)         |
| Number who were retested (%)   | 2,187 (19.6)          | 47,539 (33.6)         |
| Age ± SD, y                    | 52.9 ± 21.2           | 54.0 ± 21.3           |
| Sex female (%)                 | 1,252 (57.2)          | 27,471 (57.8)         |
| Retest positive, any (%)       | 81 (0.7)              | 7,167 (5.1)           |
| Time to positive retest ± SD, d| 181.6 ± 106.8         | 223.3 ± 93.3          |
| Retest positive, symptomatic   | 38 (0.3)              | 6,030 (4.3)           |

|                     | Any infection | Symptomatic infection | Asymptomatic infection |
|---------------------|---------------|-----------------------|------------------------|
| Effectiveness       | 85.7%         | 92.0%                 | 52.2%                  |
| 90-150 days         | 63.9%         | 82.9%                 | -34.6%                 |
| 151-210 days        | 93.2%         | 96.0%                 | 77.9%                  |
| 211-270 days        | 93.9%         | 96.3%                 | 79.8%                  |
| 271-330 days        | 91.3%         | 91.6%                 | 89.7%                  |
| 331-390 days        | 90.8%         | 88.9%                 | 100%                   |
| After 390 days      | 87.3%         | 95.0%                 | 44.0%                  |

Abbreviation: SD, standard deviation
Table 4. Long-term protection against reinfection by age group

| Age group (years) | Number of patients | Retest positive | Infection rate | Estimated protection | p-value |
|-------------------|--------------------|-----------------|----------------|----------------------|---------|
| Overall           | 11,186             | 141,470         | 81             | 7,167                | 0.7%    | 5.1% | 85.7% | -- |
| 0-17              | 368                | 6,650           | 1              | 230                  | 0.3%    | 3.5% | 92.1% | 0.26 |
| 18-34             | 2,735              | 26,832          | 14             | 1,459                | 0.5%    | 5.4% | 90.6% | 0.03 |
| 35-50             | 2,542              | 27,702          | 15             | 1,531                | 0.6%    | 5.5% | 89.3% | 0.01 |
| 51-64             | 2,630              | 34,119          | 17             | 1,671                | 0.6%    | 4.9% | 86.8% | 0.004 |
| 0-64              | 8,275              | 95,304          | 47             | 4,891                | 0.6%    | 5.1% | 88.9% | <0.001 |
| ≥65               | 2,911              | 46,166          | 34             | 2,276                | 1.2%    | 4.9% | 76.3% | … |

*p-values were calculated using age group ≥65 years as reference group*
Figure legends

Figure 1. Schematic depicting two distinct cohorts of the Delta variant analysis and long-term effectiveness analysis
